Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02843633 · ClinicalTrials.gov registry record · NA
LEADERS FREE II: BioFreedom™ Pivotal Study
A NA study of Acute Coronary Syndrome and High Bleeding Risk, sponsored by Biosensors Europe.
- Active
- Registry status
- NA
- Development phase
- 1,203
- Enrollment target
- 20
- Study locations
NCT02843633: Active NA study of Acute Coronary Syndrome and High Bleeding Risk, sponsored by Biosensors Europe.
NCT02843633 is a NA study of Acute Coronary Syndrome and High Bleeding Risk that is active but no longer recruiting, run by Biosensors Europe. The registered enrollment target is 1,203 participants, below the 2,692-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02843633, a NA study of Acute Coronary Syndrome and High Bleeding Risk, is active but no longer recruiting, sponsored by Biosensors Europe.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,203 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the Gazelle™ Bare Metal Stent arm of the Leaders Free study (NCT01623180) in high bleeding risk patients.
Conditions Studied
Interventions
- DEVICE BioFreedom™ Drug Coated Coronary Stent System
- DRUG Antiplatelet Drug
Study Locations (20)
California
- Scripps Health - La Jolla
- University of California San Diego - La Jolla
- Santa Barbara Cottage Hospital - Santa Barbara
Florida
- University of Florida Jacksonville - Jacksonville
- Velella Research - Sarasota
- Tallahassee Research Institute, Inc. - Tallahassee
Michigan
- McLaren Bay Region - Bay City
- MidMichigan Medical Center Midland - Midland
- William Beaumont Hospital - Royal Oak
Missouri
- Missouri Cardiovascular Specialists, LLP - Columbia
- Saint Luke's Hospital of Kansas City - Kansas City
Alabama
- Heart Center Research, LLC - Huntsville
Arkansas
- Tri-Lakes Research - Hot Springs
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Georgia
- North Georgia Heart Foundation - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,203 participants |
| Start Date | 2017-02-14 |
| Est. Completion | 2021-03 |
| Phase | NA |
What the registry record for NCT02843633 still lists
NCT02843633 is an interventional study that assigns participants to a tested intervention. Its 1,203 participants enrollment target places it among the larger protocols in the corpus, below the 2,692-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which BioFreedom™ Drug Coated Coronary Stent System is the first listed.
NCT02843633 names 20 study sites across 13 states, led by California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT02843633 about?
NCT02843633 is a clinical study titled "LEADERS FREE II: BioFreedom™ Pivotal Study". This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the Gazelle™ Bare Metal Stent arm of the Leaders Free study (NCT01623180) in high bleeding risk patients.
What is the current status of trial NCT02843633?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,203 participants. The study started on 2017-02-14. Estimated completion is 2021-03.
What conditions does trial NCT02843633 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome, High Bleeding Risk.
What interventions are being tested in trial NCT02843633?
The interventions under investigation include: BioFreedom™ Drug Coated Coronary Stent System (DEVICE), Antiplatelet Drug (DRUG).
Who is sponsoring clinical trial NCT02843633?
This trial is sponsored by Biosensors Europe, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02843633 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02843633's enrollment target sits among peer trials
1,203 14th of 40 higher than 27 of 40 other Acute Coronary Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Coronary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positive Emotions Following Acute Cardiac Events
RECRUITING · NA
-
Healthy Heart Habits-2
ACTIVE NOT RECRUITING · NA
-
OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study
ACTIVE NOT RECRUITING · NA
-
Post Acute Cardiac Event Smoking (PACES) Study
ACTIVE NOT RECRUITING · NA
-
Cost Comparison of Cardiac Magnetic Resonance Imaging (MRI) Use in Emergency Department (ED) Patients With Chest Pain
COMPLETED · NA
-
Mind-body Interventions in Cardiac Patients
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07038785 · 1,204 participants
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI